Routine immunization profile: Serbia

Routine immunization profile Serbia Progress towards achieving European Vaccine Action Plan goals, 2017 Goal Indicator Status Goal Indicator Status 1 Sustain polio-free status a (Current risk) Yes (Intermediate) 4 Meets vaccination coverage targets DTP3 national immunization coverage ≥95%d ≥90% DTP3 coverage achieved in ≥90% of districtse Yes Yes Yes 2 Measles elimination statusb Endemic 5 Make evidence-based decisions about introduction of new vaccines*e NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV No NN NN NNRubella elimination status b Endemic 3 Control hepatitis B infectionc Validation pending 6 Achieve financial sustainability of the national immunization programme**c Yes *New vaccines introduced or not introduced based on NITAG evidence-based recommendations **Country self-sufficient for procuring routine vaccines Demographic, income and health expenditure summary, 2017 Total Populationf 8 790 574 Live births 92 719 Surviving infants 91 940 <5 years 467 331 <15 years 1 446 414 Neonatal mortality rate (per 1000 live births)f 3.7 Infant mortality rate (per 1000 live births)f 5 Number of districtse 25 GNI (per capita, in USD)g 5180 Health spending as % of total government expenditureg 12 Immunization schedule, 2017e Birth BCG, HepB_Pediatric 4W HepB_Pediatric 8W DTaPHibIPV 14W DTaPHibIPV 20W DTaPHibIPV 5M HepB_Pediatric 12M MMR 18M DTaPHibIPV 7Y DT, MMR, OPV 14Y OPV, Td Routine immunization profile Serbia Vaccine coverage estimates, 2013-2017d Number of reported cases of vaccine- preventable diseases, 2013-2017e 2013 2014 2015 2016 2017 Measles 1 37 383 11 721 Mumps 84 63 41 40 37 Rubella 11 2 10 5 5 Congenital rubella syndrome 0 0 ND ND 0 Diphtheria 0 0 0 0 0 Tetanus 2 0 4 4 2 Pertussis 39 281 89 148 285 Hepatitis A 243 114 84 103 100 Varicella 45 305 39 391 39 272 37 738 33 058 DTP3 reported coverage by subnational area†, 2017e MCV2 reported coverage by subnational area†, 2017eMCV1 reported coverage by subnational area†, 2017e Surveillance with laboratory confirmation of cases, 2017e Measles Yes Rubella Yes Congenital rubella syndrome No Rotavirus No Invasive meningococcal disease No Invasive pneumococcal disease No Invasive Haemophilus influenzae disease No Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive Haemophilus influenzae disease. ≥95% 90-94% 80-89% <80% ND ≥95% 90-94% 80-89% <80% ND ≥95% 90-94% 80-89% <80% ND ND NR50 0100 2013 2014 2015 2016 2017 BCG 97 98 98 98 97 HepB-BD ND ND ND ND ND DTP1 98 97 98 97 98 DTP3 95 93 95 92 95 HepB3 91 92 94 91 93 Hib3 92 94 95 92 95 Pol3 97 93 95 93 95 PCV3 NR NR NR NR NR Rotac NR NR NR NR NR RCV1 93 86 86 82 86 MCV1 92 86 86 82 86 MCV2 82 91 86 90 91 Routine immunization profile Serbia Number of reported measles, mumps and rubella casese and MCV coverage estimatesd, 2013-2017 DTP1-DTP3 dropout rate, 2013-2017d Note: Dropout rate is calculated using WUENIC Reported target population, reported number of DTP3 doses administered and DTP3 reported coveragee, 2013-2017 Number of reported diphtheria, tetanus and pertussis casese and DTP3 coverage estimatesd, 2013-2017 Percentage of districts by DTP3 reported coveragee, 2013-2017 Immunization system characteristics, 2017 Sustained access to WHO accredited polio, measles, and rubella laboratoriesh Yes NITAG in place that meets six WHO criteriae No National system in place to monitor AEFIse Yes Communication plan in place to respond to vaccine safety-related eventse No Vaccine hesitancy assessment performed within last 5 years e ND Mandatory proof of immunization at school entrye Yes Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest 0 20 40 60 80 100 0 100 200 300 400 500 600 700 800 2013 2014 2015 2016 2017 % c ov er ag e N um be r o f c as es Year Measles Mumps Rubella MCV1 coverage MCV2 coverage 0 20 40 60 80 100 0 50 100 150 200 250 300 2013 2014 2015 2016 2017 % c ov er ag e N um be r o f c as es Year Diptheria Tetanus Pertussis DTP3 coverage 0 20 40 60 80 100 0 10000 20000 30000 40000 50000 60000 70000 2013 2014 2015 2016 2017 % c ov er ag e N um be r Year DTP3 reported population DTP3 reported doses DTP3 reported coverage 100 88 96 92 12 4 8 100 0 20 40 60 80 100 2013 2014 2015 2016 2017 Percentage of subnational areas Ye ar ≥90% 80-89% 50-79% <50% ND 3 4 3 5 3 0 1 2 3 4 5 6 2013 2014 2015 2016 2017 DTP1-DTP3 dropout rate (%) Ye ar Routine immunization profile Serbia Vaccine stockouts by administrative levele, 2013-2017 Abbreviations Data sources *Data on HPV stockouts have only been collected in JRF since 2016 a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC c European Vaccine Action Plan 2015-2020 Midterm report d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): (http://www.who.int/immunization/monitoring_surveillance/data/en/) e WHO/UNICEF Joint Reporting Form on immunization (JRF) f World Population Prospects: The 2017 Revision, New York, United Nations g World Bank, World Development Indicators h Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network † The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map disclaimer AEFI Adverse event following immunization MCV1 measles-mumps-rubella vaccine, first dose BCG Bacille Calmette-Guerin vaccine for tuberculosis MCV2 measles-mumps-rubella vaccine, second dose CRS congenital Rubella Syndrome MMR measles-mumps-rubella vaccine DT diptheria-tetanus-containing vaccine ND Data not available DTP diptheria-tetanus-pertussis-containing vaccine NITAG National Immunization Technical Advisory Group DTP1 diphtheria-tetanus-pertussis-containing vaccine, first dose NN No NITAG DTP3 diphtheria-tetanus-pertussis-containing vaccine, third dose NR Not relevant as vaccine not included in immunization schedule GNI Gross national income OPV oral polio vaccine HepB hepatitis B PCV pneumococcal conjugate vaccine HepB3 hepatitis B vaccine, third dose PCV3 pneumococcal conjugate vaccine , third dose HepB-BD hepatitis B vaccine, birth dose Pol3 polio-containing vaccine, third dose Hib Haemophilus influenzae type b RCV1 rubella-containing vaccine, first dose Hib3 Haemophilus influenzae type b vaccine, third dose Rotac rotavirus vaccine-complete series HPV human papillomavirus Td tetanus-diphtheria-containing vaccine IPV inactivated polio vaccine TT tetanus toxoid vaccine MCV measles-containing vaccine W,M,Y Weeks, Months, Years No stockout Subnational level stockout only National level stockout only Stockout at both levels NR ND 2013 2014 2015 2016 2017 BCG ND ND No No No DTP ND ND No No No HepB ND ND No No No Hib ND ND No No No Pneumo ND ND No No No Rota NR NR NR NR NR OPV ND ND Both No No IPV ND ND No No No Measles ND ND Both No No HPV * * * NR NR TT ND ND No No No ©World Health Organization 2019